Alzheimer’s treatment donanemab is not a ‘miracle drug’ – not providing it on the NHS is the right choice
There is a lot of outrage that the new Alzheimer’s drug donanemab is being refused on the NHS. But there are good reasons for ...
Medpage Today on MSN4d
Brain Edema Risk May Be Lower With Modified Donanemab Dosing
The standard dosing regimen was 700 mg of donanemab for the first three infusions, then 1,400 mg for each infusion after that ...
Donanemab trial patient: ‘I feel as normal as a 78-year-old can be’
A retired journalist who took part in the clinical trial for the new Alzheimer’s drug has described how he feels “as normal ...
Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS
Help us keep bring these critical stories to light. Your support makes all the difference. The drug Donanemab has been found ...
Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study
Eli Lilly and Company (NYSE: LLY) today announced positive results from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a ...
Monthly Prescribing Reference3d
Study Shows Modified Donanemab Titration Regimen Cuts Risk of ARIA-E
Modified titration was associated with a 41% lower relative risk of ARIA-E than the standard dosing regimen. Topline results were announced from a phase 3b trial evaluating various dosing regimens of ...
News Medical on MSN6d
MHRA greenlights donanemab for early stage Alzheimer’s disease
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the ...
Eli Lilly says Donanemab redudced ARIA-E in early Alzheimer’s patients
Eli Lilly (LLY) announced “positive results” from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a reduction in amyloid-related ...
openaccessgovernment9d
Donanemab: NHS rejects second promising drug for Alzheimer’s
A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England ...
ITV9d
Alzheimer’s drug rejected for NHS use: What is Donanemab?
This comes as the Medicines and Healthcare Products Regulatory Agency (MHRA) said in August the drug, Donanemab, manufactured by pharmaceutical giant Eli Lilly, could be licensed for use in the UK.
Alzheimer’s drug approved in the UK, but it won’t be available on the NHS – here’s why
The UK’s drugs regulator – the MHRA – has approved the Alzheimer’s drug donanemab, but it won’t be available on the NHS.
Alzheimer's 'wonder drug' Donanemab blocked for use on NHS over cost concerns
A drug that can slow the progression of Alzheimer's disease has been blocked for use on the NHS due to cost concerns.